Vizsgálati helyszín
Poliklinika Borzan d.o.o.
Osijek, 31000, HorvátországEU-13 felzárkózó országMég nincs intézményhez kötve
- 19futó vizsgálat
- 10lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 29 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis15 vizsgálat
- 3. fázis13 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult10 vizsgálat
- Toboroz9 vizsgálat
- Fut, nem toboroz8 vizsgálat
- Még nem toboroz2 vizsgálat
- Fő szponzor
- AbbVie5 vizsgálat
- Hoffmann-La Roche4 vizsgálat
- Sanofi-Aventis Recherche & Developpement3 vizsgálat
- Abivax S.A.2 vizsgálat
- Eli Lilly & Co.2 vizsgálat
- és még 11
Futó vizsgálatok
Toboroz
A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
2025-524404-29-00· 2. fázis· Eli Lilly & Co.· Forrás
Meghívásos bevonás
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease
2025-522001-38-00· 2. fázis· Mirador Therapeutics Inc.· Forrás
Toboroz
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· 3. fázis· AbbVie· Forrás
Toboroz
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
2023-507853-13-00· 2. fázis· Eli Lilly & Co.· Forrás
Toboroz
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· 2. fázis· AbbVie· Forrás
Toboroz
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
2023-506150-21-00· 2. fázis· Dr. Falk Pharma GmbH· Forrás
Fut, nem toboroz
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102· 3. fázis· AbbVie· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek